Your browser doesn't support javascript.
loading
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis.
Silverstein, William K; Zipursky, Jonathan S; Amaral, Andre C; Leis, Jerome A; Strong, Laura; Nardi, Julie; Weinerman, Adina S; Wong, Brian M; Stroud, Lynfa.
Afiliação
  • Silverstein WK; Department of Medicine, University of Toronto, Toronto, Canada. william.silverstein@mail.utoronto.ca.
  • Zipursky JS; Department of Medicine, University of Toronto, Toronto, Canada.
  • Amaral AC; Division of Clinical Pharmacology & Toxicology, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Leis JA; Department of Medicine, University of Toronto, Toronto, Canada.
  • Strong L; Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Nardi J; Department of Medicine, University of Toronto, Toronto, Canada.
  • Weinerman AS; Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Wong BM; Integrated Community Program, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Stroud L; Department of Respiratory Therapy, Sunnybrook Health Sciences Centre, Toronto, Canada.
J Gen Intern Med ; 38(5): 1160-1166, 2023 04.
Article em En | MEDLINE | ID: mdl-36662403
ABSTRACT

BACKGROUND:

Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) capacity is unknown.

OBJECTIVE:

To describe how our hospital operationalized the use of HFNC on GIM wards, assess its impact on ICU capacity, and examine the characteristics and outcomes of treated patients.

DESIGN:

Retrospective cohort study of all patients treated with HFNC on GIM wards at a Canadian tertiary care hospital.

PARTICIPANTS:

All patients admitted with COVID-19 and treated with HFNC on GIM wards from December 28, 2020, to June 13, 2021, were included. MAIN

MEASURES:

We combined administrative data on critical care occupancy daily with chart-abstracted data for included patients to establish the total number of patients receiving ICU-level care at our hospital per day. We also collected data on demographics, medical comorbidities, illness severity, COVID-19 treatments, HFNC care processes, and patient outcomes. KEY

RESULTS:

We treated 124 patients with HFNC on the GIM wards (median age 66 years; 48% female). Patients were treated with HFNC for a median of 5 days (IQR 3 to 8); collectively, they received HFNC for a total of 740 hospital days, 71% of which were on GIM wards. At peak ICU capacity strain (144%), delivering HFNC on GIM wards added 20% to overall ICU capacity by managing up to 14 patients per day. Patients required a median maximal fraction of inspired oxygen of 80% (IQR 60 to 95). There were 18 deaths (15%) and 85 patients (69%) required critical care admission; of those, 40 (47%) required mechanical ventilation.

CONCLUSIONS:

With appropriate training and resources, treatment of COVID-19 patients with HFNC on GIM wards appears to be a feasible strategy to increase critical care capacity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article